Viracta Net Working Capital vs Current Deferred Revenue Analysis

VIRX Stock  USD 0.16  0.02  14.29%   
Viracta Therapeutics financial indicator trend analysis is much more than just breaking down Viracta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viracta Therapeutics is a good investment. Please check the relationship between Viracta Therapeutics Net Working Capital and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Net Working Capital vs Current Deferred Revenue

Net Working Capital vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viracta Therapeutics Net Working Capital account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Viracta Therapeutics' Net Working Capital and Current Deferred Revenue is -0.12. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Viracta Therapeutics, assuming nothing else is changed. The correlation between historical values of Viracta Therapeutics' Net Working Capital and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Viracta Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Working Capital i.e., Viracta Therapeutics' Net Working Capital and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.12
Relationship DirectionNegative 
Relationship StrengthInsignificant

Net Working Capital

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.
Most indicators from Viracta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.Sales General And Administrative To Revenue is likely to rise to 53.81 in 2024, whereas Selling General Administrative is likely to drop slightly above 13.7 M in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense491K577K3.7M3.9M
Depreciation And Amortization178K210K492K324.1K

Viracta Therapeutics fundamental ratios Correlations

0.150.19-0.020.670.16-0.06-0.480.650.340.690.550.571.0-0.150.60.250.150.74-0.020.130.171.0-0.2-0.140.3
0.150.470.210.03-0.380.510.640.09-0.36-0.35-0.29-0.140.17-0.030.190.660.00.130.30.11-0.340.180.23-0.010.44
0.190.470.68-0.14-0.360.720.32-0.02-0.22-0.21-0.37-0.140.220.11-0.040.520.01-0.040.230.39-0.320.220.210.130.25
-0.020.210.68-0.2-0.230.250.410.0-0.02-0.3-0.270.03-0.010.180.340.34-0.25-0.230.190.21-0.18-0.010.820.20.63
0.670.03-0.14-0.20.17-0.16-0.380.10.410.50.550.670.650.10.480.13-0.540.77-0.15-0.640.290.66-0.180.160.14
0.16-0.38-0.36-0.230.17-0.07-0.220.490.140.120.8-0.140.11-0.270.0-0.060.070.19-0.93-0.060.980.12-0.2-0.270.0
-0.060.510.720.25-0.16-0.070.43-0.1-0.53-0.36-0.32-0.52-0.040.09-0.470.40.01-0.11-0.130.17-0.03-0.04-0.110.1-0.1
-0.480.640.320.41-0.38-0.220.43-0.33-0.49-0.92-0.5-0.45-0.470.09-0.130.64-0.19-0.320.050.0-0.17-0.470.470.120.45
0.650.09-0.020.00.10.49-0.1-0.330.280.510.620.190.63-0.470.50.030.540.32-0.290.510.390.63-0.01-0.510.36
0.34-0.36-0.22-0.020.410.14-0.53-0.490.280.450.40.80.33-0.080.43-0.22-0.20.23-0.09-0.210.150.320.03-0.070.25
0.69-0.35-0.21-0.30.50.12-0.36-0.920.510.450.50.560.69-0.130.38-0.510.20.470.10.050.080.68-0.33-0.15-0.22
0.55-0.29-0.37-0.270.550.8-0.32-0.50.620.40.50.320.5-0.360.42-0.09-0.020.55-0.68-0.170.810.51-0.19-0.340.12
0.57-0.14-0.140.030.67-0.14-0.52-0.450.190.80.560.320.57-0.070.63-0.09-0.310.410.2-0.32-0.090.570.09-0.040.33
1.00.170.22-0.010.650.11-0.04-0.470.630.330.690.50.57-0.130.590.250.170.710.020.160.121.0-0.2-0.120.29
-0.15-0.030.110.180.1-0.270.090.09-0.47-0.08-0.13-0.36-0.07-0.13-0.09-0.02-0.38-0.060.3-0.29-0.21-0.130.181.0-0.04
0.60.19-0.040.340.480.0-0.47-0.130.50.430.380.420.630.59-0.090.2-0.170.530.17-0.060.030.60.5-0.080.76
0.250.660.520.340.13-0.060.40.640.03-0.22-0.51-0.09-0.090.25-0.020.2-0.090.28-0.090.090.020.260.150.020.59
0.150.00.01-0.25-0.540.070.01-0.190.54-0.20.2-0.02-0.310.17-0.38-0.17-0.09-0.150.070.89-0.10.15-0.36-0.46-0.18
0.740.13-0.04-0.230.770.19-0.11-0.320.320.230.470.550.410.71-0.060.530.28-0.15-0.12-0.270.260.73-0.31-0.020.2
-0.020.30.230.19-0.15-0.93-0.130.05-0.29-0.090.1-0.680.20.020.30.17-0.090.07-0.120.16-0.950.010.240.280.03
0.130.110.390.21-0.64-0.060.170.00.51-0.210.05-0.17-0.320.16-0.29-0.060.090.89-0.270.16-0.210.15-0.02-0.350.07
0.17-0.34-0.32-0.180.290.98-0.03-0.170.390.150.080.81-0.090.12-0.210.030.02-0.10.26-0.95-0.210.13-0.16-0.20.05
1.00.180.22-0.010.660.12-0.04-0.470.630.320.680.510.571.0-0.130.60.260.150.730.010.150.13-0.2-0.120.3
-0.20.230.210.82-0.18-0.2-0.110.47-0.010.03-0.33-0.190.09-0.20.180.50.15-0.36-0.310.24-0.02-0.16-0.20.190.69
-0.14-0.010.130.20.16-0.270.10.12-0.51-0.07-0.15-0.34-0.04-0.121.0-0.080.02-0.46-0.020.28-0.35-0.2-0.120.19-0.02
0.30.440.250.630.140.0-0.10.450.360.25-0.220.120.330.29-0.040.760.59-0.180.20.030.070.050.30.69-0.02
Click cells to compare fundamentals

Viracta Therapeutics Account Relationship Matchups

Viracta Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets37.2M48.3M108.6M96.0M56.7M54.4M
Short Long Term Debt Total6.3M6.2M5.5M25.2M25.6M14.3M
Other Current Liab2.5M3.4M5.4M6.9M10.1M5.5M
Total Current Liabilities9.4M6.3M9.1M10.0M38.4M40.3M
Total Stockholder Equity27.5M(46.2M)94.4M61.1M18.3M19.5M
Property Plant And Equipment Net820K1.0M882K414K464K749.7K
Net Debt(12.0M)(40.9M)(98.1M)(11.6M)13.2M13.9M
Retained Earnings(682.8M)(50.9M)(165.7M)(214.9M)(265.9M)(279.2M)
Accounts Payable791K1.6M2.9M2.5M2.4M1.7M
Cash18.3M47.1M103.6M36.8M12.3M24.1M
Non Current Assets Total918.0K1.1M3.3M2.2M1.7M1.1M
Non Currrent Assets Other98.0K76K2.4M1.8M1.3M1.3M
Cash And Short Term Investments34.6M47.1M103.6M91.0M53.7M51.5M
Common Stock Shares Outstanding2.5M92.8K31.9M37.8M38.6M40.6M
Liabilities And Stockholders Equity37.2M48.3M108.6M96.0M56.7M54.4M
Non Current Liabilities Total8K281.0K88.2M5.1M24.9M0.0
Other Current Assets1.7M220K3.4M4.5M857K1.6M
Other Stockholder Equity698.6M4.7M254.6M270.7M278.8M292.7M
Total Liab9.7M94.5M14.2M34.9M38.4M27.6M
Property Plant And Equipment Gross820K273K882K414K464K717.8K
Total Current Assets36.3M47.2M105.3M93.7M55.0M52.9M
Accumulated Other Comprehensive Income1K(5.5M)0.0(178K)9K9.5K
Short Term Debt6.0M1.4M762K556K25.8M27.1M
Common Stock3K4K11K1K4.6K4.9K
Capital Surpluse698.6M718.8M254.6M270.7M243.6M436.4M
Property Plant Equipment117.1K1.0M242K148K170.2K245.8K
Other Assets1.076.4K0.01.8M2.1M2.2M
Net Tangible Assets(28.4M)(46.2M)89.2M55.7M64.0M67.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.